로딩 중…
지수 로딩 중…
텔콘RF제약
200230· KOSDAQ· Information Technology· Technology Hardware & Equipment
₩2,180+1.87%
2026-09-18
Financials
Valuation Metrics
텔콘RF제약's Market Cap is ₩207B. At end of 2025 it was ₩726B. Ranked #2312 of 2,421 in KR market (top 95%), #1544 of 1,640 on KOSDAQ (top 94%), #234 of 246 in Technology Hardware & Equipment (top 95%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 20.67B KRW | KR#2,312/2,421 Sec#234/246 |
| Revenue | 61.78B KRW | KR#1,685/2,421 Sec#165/246 |
| Net Income | -28.73B KRW | KR—/2,421 Sec—/246 |
| Total Assets | 187.22B KRW | KR#1,360/2,421 Sec#118/246 |
| Net Assets | 99.48B KRW | KR#1,419/2,421 Sec#130/246 |
| Employees | 133 | KR#1,415/2,421 Sec#118/246 |
| Value | ||
| P/B | 0.21x | KR#134/2,421 Sec#9/246 |
| P/S | 0.33x | KR#648/2,421 Sec#61/246 |
| EV/EBITDA | 163.95x | KR#1,522/2,421 Sec#139/246 |
| FCF Yield | 6.51% | KR#763/2,421 Sec#62/246 |
| Profitability | ||
| ROE | -28.87% | KR#2,174/2,421 Sec#221/246 |
| ROA | -15.34% | KR#2,194/2,421 Sec#225/246 |
| Op. Margin | 0.62% | KR#1,545/2,421 Sec#144/246 |
| Revenue Growth | 50.63% | KR#205/2,421 Sec#26/246 |
| Financial Health | ||
| Debt Ratio | 88.19% | KR#1,443/2,421 Sec#160/246 |
| Total Debt | 60.05B KRW | KR#932/2,421 Sec#79/246 |
| FCF | 1.35B KRW | KR#1,125/2,421 Sec#98/246 |
| Cash | 17.46B KRW | KR#1,326/2,421 Sec#130/246 |
| Current Ratio | 0.90x | KR#1,843/2,421 Sec#200/246 |
| Performance | ||
| 1Y Return | -80.09% | KR#2,353/2,421 Sec#237/246 |
| 1M Return | -5.22% | KR#1,808/2,421 Sec#193/246 |
| From 52W High | -84.97% | KR#2,387/2,421 Sec#243/246 |
| 1Y MDD | -86.08% | KR#2,378/2,421 Sec#243/246 |
| Trading | ||
| Volume | 10,657 shares | KR#1,886/2,421 Sec#194/246 |
| Trading Value | 23.3M KRW | KR#2,107/2,421 Sec#212/246 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/246 |
| Per Share | ||
| EPS | -3,029 KRW | KR—/2,421 Sec—/246 |
| BPS | 10,492 KRW | KR#958/2,421 Sec#82/246 |
Company Info
동사는 1999년 설립되어 RF사업과 완제의약품 제조업을 병행하며 2014년 코스닥에 상장함. 제약·바이오 부문은 KGMP 생산시설을 바탕으로 다양한 제형의 제품을 생산하고 외주생산을 통해 매출 확대 및 신약개발에 투자하고 있음. RF부문은 광 사업장을 확대하며 광전복합 커넥터와 광Cable Ass’y 공급을 통해 광 솔루션 업체로 도약을 준비하고 5G 관련 솔루션 및 동남아시아 시장 진출을 통해 경쟁력 강화에 집중하고 있음. 텔콘RF제약는 1999년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.